The Microsetta Initiative studies human microbiomes, analyzing diverse data to reveal links between microbes, diet, and health for improved public health.
Health Canada approves FYB201/Ranopto® (Ranibizumab), a biosimilar to Lucentis® – Biotech Investments
EQS-News: Formycon AG / Key word(s): Regulatory Approval Health Canada approves FYB201/Ranopto® (Ranibizumab), a biosimilar to Lucentis® 07.12.2023 / 07:30 CET/CEST The issuer is solely